FDA Grants Accelerated Approval to Sacituzumab Govitecan-hziy to Treat Metastatic TNBC

The FDA granted a breakthrough therapy designation and priority review under its Accelerated Approval Program to sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer.

Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news